企業プロフィール · Healthcare

Carl Zeiss Meditec AG

AFX · XETRA
取引所
XETRA
国 / 地域
Germany
従業員数
5,798
現在値
24.94
リアルタイム · 2026年6月22日
妥当買付価格
≤ €26
安全マージンの起点
ベイリー成長スコア
38/100
やや弱い
本源的価値 · 3 段階レンジ 現在値 €24.94 リアルタイム · 保守的な本源的価値レンジ内 · 十分な安全マージン

総合バリュエーションレンジ · 保守的 €24–€26 / 妥当 €29–€41 / 楽観的 €47–€54。€24.94 時点で 保守的な本源的価値レンジ内 · 十分な安全マージン。

レポート公開時 €27.96(2026年6月26日)

2026年5月22日 Update Needs review

Carl Zeiss Meditec appoints Bronwyn Brophy O'Connor as CEO

Carl Zeiss Meditec appointed Bronwyn Brophy O'Connor as CEO, succeeding Maximilian Foerst after his code-of-conduct departure.

Possible impact:May affect investor expectations for governance stability and execution of the turnaround plan.

2026年5月12日 Earnings Needs review

Carl Zeiss Meditec plans cost cuts and lowers revenue outlook

Carl Zeiss Meditec announced a cost program affecting up to 1,000 jobs and guided FY revenue to EUR 2.15-2.20 billion.

Possible impact:May affect expectations for China headwinds, margin recovery timing and execution of planned savings.

Automatically summarized from public sources; for context only, not investment advice.

時価総額€24.3億
売上高(TTM)€21.68億
EBITDA€2.17億
純利益率4.38%
ROE4.54%
PER (TTM)20.26
予想PER14.73
PEG0.86
EPS€1.37
配当利回り2.04%
52週レンジ€22.12 – €56.77

データ提供:EODHD、報告通貨で表示。参考情報であり、投資助言ではありません。

Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, North America, and Asia. It operates in two segments, Ophthalmology and Microsurgery. The Ophthalmology segment offers products and solutions for the diagnosis and treatment of chronic eye diseases, including slit lamps, refractometers, and tonometers; optical coherence tomography and fundus cameras for retina examination; functional glaucoma diagnostic devices (perimeters); surgical ophthalmology products comprising surgical microscopes, biometers, and phacoemulsification and vitrectomy equipment; intraocular lenses for cataract surgery; and systems and consumables for laser eye surgery that include the VISUMAX femtosecond laser, which enables minimally invasive correction of vision defects using lenticular extraction, as well as digital products for the storage, analysis, and sharing of clinical data. The Microsurgery segment provides products and solutions for minimally invasive surgical treatments, including surgical visualization, interoperative radiotherapy, interoperative pathology, special surgical instruments, and digital solutions, as well as the ZEISS Tumor Workflow, a cross-product workflow solution. It serves physicians in various fields and hospitals. The company has a strategic collaboration with Envision Health Technologies Inc. to help advance glaucoma care through gamified virtual reality technology. The company was founded in 1846 and is headquartered in Jena, Germany. Carl Zeiss Meditec AG operates as a subsidiary of ZEISS Group.

沿革

近日公開このセクションは現在準備中です。近日公開予定です。

業界での地位

近日公開このセクションは現在準備中です。近日公開予定です。

この銘柄のレポートはお使いの言語でまだありません。